Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of TAK-861 in narcolepsy type 1
2023-508462-15-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Primary endpoint: Occurrence of at least 1 treatment-emergent adverse event. Planned start Apr 2023; status: authorised.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on 2023-508462-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508462-15-00.